-
-
Concert persuades FDA to keep breakthrough tag for alopecia therapy despite Lilly’s arrival
-
AlloVir’s cell therapy tackles infection in midphase kidney transplant trial
Tasso lassos EU approval for at-home high-volume blood collection device
Arrowhead’s $3.7B J&J deal is done, CEO says, after ‘out of the blue’ NASH decision
Titan Medical, already down to bare bones, lays off almost half of executive team
In The News
- Economic Storm Clouds Hovering Over Trump and Global Leaders August 25, 2019 By News Team
- UN: Possible to Eradicate Malaria, but Probably Not Soon August 24, 2019 By News Team
- Climate Change Turns Arctic Into Strategic, Economic Hotspot August 23, 2019 By News Team
Biotechnology Daily
more-
GSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal trial
GSK’s head of vaccine R&D, Phil Dormitzer, M.D., Ph.D., can almost taste regulatory success as…
Concert persuades FDA to keep breakthrough tag for alopecia therapy despite Lilly’s arrival
AlloVir’s cell therapy tackles infection in midphase kidney transplant trial
Tasso lassos EU approval for at-home high-volume blood collection device
Pharnext ditches Alzheimer’s plans, saying more development would be too costly
Market Watch
more-
Bluebird Bio Shares Down After Fourth-Quarter-Revenue Decline
Bluebird Bio Inc. shares were down about 24%, to $3.28, in Wednesday midday trading after…
Intel’s stock set for best month in 22 years as execs lay out plans to take on AMD’s rise in servers
Fosun International Shares Drop After 2022 Earnings Miss Estimates
Rivian Shares Up About 10% After Positive Report From Needham
U.S. stocks finish slightly lower as higher Treasury yields weigh on tech shares
Bio Business News
moreArrowhead’s $3.7B J&J deal is done, CEO says, after ‘out of the blue’ NASH decision
Hours after Arrowhead Pharmaceuticals revealed that Johnson & Johnson is…
Titan Medical, already down to bare bones, lays off almost half of executive team
Hot on the heels of Titan Medical’s announcement last week…
Biogen’s brand-new CEO shuns ‘desperation factor’ but signals major business development ahead
Biogen’s new CEO Christopher Viehbacher has wasted no time getting…
World News
moreStocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
GSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal trial
Concert persuades FDA to keep breakthrough tag for alopecia therapy despite Lilly’s arrival
AlloVir’s cell therapy tackles infection in midphase kidney transplant trial
Tasso lassos EU approval for at-home high-volume blood collection device
Arrowhead’s $3.7B J&J deal is done, CEO says, after ‘out of the blue’ NASH decision
Titan Medical, already down to bare bones, lays off almost half of executive team
Biogen’s brand-new CEO shuns ‘desperation factor’ but signals major business development ahead
Biogen bails on BTK race just 19 months after placing $125M bet
Bluebird Bio Shares Down After Fourth-Quarter-Revenue Decline
Intel’s stock set for best month in 22 years as execs lay out plans to take on AMD’s rise in servers